Jazz Pharmaceuticals director proposes $3.36M sale

Jazz Pharmaceuticals (JAZZ) reported positive Phase 3 trial results for Ziihera in combination with chemotherapy, showing a 24% reduction in death risk versus trastuzumab. The trial, conducted with BeOne Medicines, found nearly 40% of patients alive at three years with a median overall survival of 27 months. JAZZ shares were down 1.11% on the Nasdaq.

Jazz Pharmaceuticals (JAZZ) presented Phase 3 trial results showing its drug Ziihera, combined with chemotherapy, extended survival in HER2-positive stomach cancer patients. The trial reported a median overall survival of 27.0 months for the Ziihera combination, compared to 19.6 months for the standard treatment. The FDA approved two Ziihera-containing regimens in August 2026. The trial involved 914 patients across 225 sites in over 30 countries.

Jazz Pharmaceuticals (JAZZ) reported updated results from the Phase 3 HERIZON-GEA-01 trial, showing Ziihera® (zanidatamab-hrii) combinations improved overall survival in HER2+ advanced gastroesophageal adenocarcinoma. Key findings: 39.8% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, median OS of 27.0 months. Ziihera plus chemotherapy reduced death risk by 24% vs. trastuzumab. Results presented at ESMO 2026.

Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera plus chemotherapy reduced death risk by 24% vs. trastuzumab plus chemo, with 40% survival at three years for Ziihera+tislelizumab+chemo. The data supports FDA-approved first-line use. Investors should monitor adoption, sales, and potential label expansions.

Jazz Pharmaceuticals' Ziihera (zanidatamab) plus chemotherapy showed improved overall survival in HER2+ advanced gastroesophageal adenocarcinoma (GEA) patients. Median OS reached 27.0 months with Ziihera plus tislelizumab and chemotherapy, reducing death risk by 35%. Nearly 40% of patients were alive at three years. Ziihera plus chemotherapy alone also showed a 24% reduction in death risk. The results were presented at a medical conference.

Jazz Pharmaceuticals announced that Samantha Pearce, its Executive Vice President and Chief Commercial Officer, will retire. Her departure is effective upon the appointment of a successor or by June 30, 2027, according to the company. The board will consider both internal and external candidates for the role.